Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

NCT00492388 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision not to continue development

Conditions

Pain
Cancer

Interventions

DRUG: PMI-150 (intranasal ketamine)
DRUG: placebo

Sponsor

Hospira, now a wholly owned subsidiary of Pfizer